Company record · RANI · Pharmaceutical Preparations
Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc.'s chief financial officer on the record is Nicholas M. Maestas, effective June 29, 2026, per the filing record.
The record holds 1 verified CFO change for Rani Therapeutics Holdings, Inc. from Form 8-K filings, filed June 30, 2026 and the CFO signature on its 10-K filed March 26, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Nicholas M. Maestas |
| Title as printed | Chief Financial Officer (principal financial officer and principal accounting officer) |
| Basis | Latest move: transition, 8-K filed June 30, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-06-30Transition
Rani Therapeutics Holdings, Inc. CFO transition: Nicholas M. Maestas to succeed Svai Sanfordeffective June 29, 2026 · 8-K filed June 30, 2026 · sec.gov, Item 5.02
2026-03-2610-K signature
Svai Sanford signed the annual report as Chief Financial Officer (Principal Financial and Accounting Officer)
10-K filed March 26, 2026 · sec.gov
“/s/ Svai Sanford Chief Financial Officer March 26, 2026 Svai Sanford (Principal Financial and Accounting Officer)”
Company
| Ticker | RANI |
|---|---|
| SEC CIK | 0001856725 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-04-16 also names Svai Sanford alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-08-04, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.